lf Thermodiagnostics is the leader in next-generation, non-invasive medical thermometry, providing solutions to physicians to discover and remediate disease. The company has engineered an FDA-cleared, whole-body early-detection system as an adjunct diagnostic tool, called AlfaSight™. AlfaSight™ is grounded in the established science of regulation thermography which was commercialized in Germany more than 25 years ago.

The AlfaSight™ regulation thermometry™ system provides a visual representation of the responsiveness of the autonomic nervous system, which can uncover the causal factors of many diseases. It is a proven, accurate technology supported by more than 100,000 patient assessments, and has been clinically correlated with hundreds of MRI & CT scans. AlfaSight™ is significantly different from infrared camera technology, which captures heat map images.

Founder Dr. Daniel Beilin led the United States FDA clearance of the first-generation regulation thermography technology in 1996 and also ushered Alfa's next-generation regulation thermometry™ system through FDA clearance. He is recognized worldwide as the foremost authority on whole-body thermometry and is supported by leaders in the fields of radiology, neurobiology and regulation medicine.

AlfaSight™ is a non-invasive patient assessment tool that identifies a wide range of physiological dysfunction by analyzing skin temperature changes over time. It can dramatically improve the accuracy of routine testing for a wide range of impaired health conditions when used as an adjunct technology to mammography and other anatomical imaging devices.